Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Dermatology

Journal Scan / Research · December 11, 2024

Efficacy and Safety of Treatment With Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

JAMA Dermatology

 

Additional Info

JAMA Dermatology
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial
JAMA Dermatol 2024 Nov 27;[EPub Ahead of Print], S Ständer, G Yosipovitch, FJ Legat, A Reich, C Paul, D Simon, L Naldi, M Metz, A Tsianakas, A Pink, S Fage, G Micali, E Weisshaar, H Sundaram, A Metelitsa, M Augustin, A Wollenberg, B Homey, MC Fargnoli, H Sofen, NJ Korman, L Skov, X Chen, ZK Jabbar-Lopez, C Piketty, SG Kwatra

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading